biostudies-literatureUnknown48(3)Verrienti AUniversità degli Studi di Roma La Sapienza<h4>Purpose</h4>Papillary thyroid carcinoma (PTC) is the most common malignant thyroid neoplasm, accounting for approximately 85% of all follicular cell-derived thyroid nodules. This study aimed to assess the diagnostic potential of circulating microRNA-146a-5p and microRNA-221-3p as biomarkers for PTC and their usefulness in monitoring disease progression during patient follow-up.<h4>Methods</h4>An observational study was conducted on two cohorts of PTC patients and healthy controls (HCs) using digital PCR. We collected patients' clinical, biochemical, and imaging data during the post-surgery surveillance. We analyzed the levels of circulating miRNAs in serum samples of patients before surgery and during the follow-up, including those with indeterminate/biochemical incomplete response (InJournal of endocrinological investigation619-631https://www.ebi.ac.uk/biostudies/studies/S-EPMC11876262biostudies-literatureSerum microRNA-146a-5p and microRNA-221-3p as potential clinical biomarkers for papillary thyroid carcinoma.PMC11876262Verrienti ADi Gioia CSponziello MDel Gatto VMaranghi MGrani GFiletti SDurante CGiacomelli LBiffoni MPecce VBarp SfalseSerum microRNA-146a-5p and microRNA-221-3p as potential clinical biomarkers for papillary thyroid carcinoma.<h4>Purpose</h4>Papillary thyroid carcinoma (PTC) is the most common malignant thyroid neoplasm, accounting for approximately 85% of all follicular cell-derived thyroid nodules. This study aimed to assess the diagnostic potential of circulating microRNA-146a-5p and microRNA-221-3p as biomarkers for PTC and their usefulness in monitoring disease progression during patient follow-up.<h4>Methods</h4>An observational study was conducted on two cohorts of PTC patients and healthy controls (HCs) using digital PCR. We collected patients' clinical, biochemical, and imaging data during the post-surgery surveillance. We analyzed the levels of circulating miRNAs in serum samples of patients before surgery and during the follow-up, including those with indeterminate/biochemical incomplete response (In2025-01-01T00:00:00Z2025 Mar2025-04-04T01:12:13.383Z2025-04-04T01:12:13.383ZS-EPMC118762623929811310.1007/s40618-024-02467-3